The estimated Net Worth of Daniel R Passeri is at least $1.56 Milion dollars as of 14 August 2023. Mr. Passeri owns over 3,000 units of Cue Biopharma Inc stock worth over $79,401 and over the last 22 years he sold CUE stock worth over $284,828. In addition, he makes $1,198,610 as Chief Executive Officer a Director at Cue Biopharma Inc.
Daniel has made over 34 trades of the Cue Biopharma Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of CUE stock worth $8,580 on 14 August 2023.
The largest trade he's ever made was exercising 377,667 units of Cue Biopharma Inc stock on 2 May 2013 worth over $917,731. On average, Daniel trades about 37,025 units every 123 days since 2003. As of 14 August 2023 he still owns at least 134,578 units of Cue Biopharma Inc stock.
You can see the complete history of Mr. Passeri stock trades at the bottom of the page.
Daniel R. Passeri J.D. serves as Chief Executive Officer, Director of the Company. He served as a director of Curis, Inc. (Nasdaq: CRIS) (“Curis”), a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancer, from September 2001 to June 2016. Mr. Passeri previously served as Chief Executive Officer of Curis from September 2001 until June 2014 and as Vice Chairman of its board of directors from June 2014 to June 2016, and additionally held the title of President from September 2001 to February 2013. Previously, from November 2000 to September 2001, Mr. Passeri served as the Senior Vice President, Corporate Development and Strategic Planning of Curis. From December 2014 to June 2015, Mr. Passeri served as Chief Officer of Technology Management and Business Development of the Jackson Laboratory for Genomic Medicine. From March 1997 to November 2000, Mr. Passeri was employed by GeneLogic Inc., a biotechnology company, most recently as Senior Vice President, Corporate Development and Strategic Planning. From February 1995 to March 1997, Mr. Passeri was employed by Boehringer Mannheim, a pharmaceutical, biotechnology and diagnostic company, as Director of Technology Management. Mr. Passeri received a J.D. from the National Law Center at George Washington University, an M.Sc. in biotechnology from the Imperial College of Science, Technology and Medicine at the University of London and a B.S. in biology from Northeastern University.
As the Chief Executive Officer a Director of Cue Biopharma Inc, the total compensation of Daniel Passeri at Cue Biopharma Inc is $1,198,610. There are 1 executives at Cue Biopharma Inc getting paid more, with Anish Suri having the highest compensation of $4,559,810.
Daniel Passeri is 59, he's been the Chief Executive Officer a Director of Cue Biopharma Inc since 2019. There are 9 older and 10 younger executives at Cue Biopharma Inc. The oldest executive at Cue Biopharma Inc is Frederick Driscoll, 70, who is the Independent Director.
Daniel's mailing address filed with the SEC is C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON, MA, 02135.
Over the last 7 years, insiders at Cue Biopharma Inc have traded over $1,426,672 worth of Cue Biopharma Inc stock and bought 1,194,685 units worth $5,848,356 . The most active insiders traders include Daniel R Passeri, Aaron G.L. Fletcher a Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,162. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth $11,040.
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Cue Biopharma Inc executives and other stock owners filed with the SEC include: